Sionna Therapeutics, Inc.
SION- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002036042
In the last 90 days, Sionna Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 146 institutions reported holding it in 13F filings for Q2 2026, worth $2.11B in total; Viking Global Investors is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:18 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Mar 2, 2026 |
| Operating expenses | $89.0M |
| Research and development | $60.3M |
| Selling, general and administrative | $28.7M |
| Operating income | -$89.0M |
| Income tax | $0 |
| Net income | -$75.3M |
| EPS, basic | $-1.88 |
| EPS, diluted | $-1.88 |
| Weighted shares, basic | 40.0M |
| Weighted shares, diluted | 40.0M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Mar 2, 2026 |
| Cash and equivalents | $58.5M |
| Total current assets | $241.4M |
| Property, plant and equipment | $2.23M |
| Total assets | $326.0M |
| Total current liabilities | $11.7M |
| Total liabilities | $19.1M |
| Shareholders' equity | $306.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Mar 2, 2026 |
| Operating cash flow | -$66.3M |
| Capital expenditures | $377.0K |
| Free cash flow | -$66.7M |
| Stock-based compensation | $12.1M |
| Investing cash flow | -$118.7M |
| Financing cash flow | $205.7M |
| Net change in cash | $20.7M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.